ALKERMES | ALKS - Umsatzkosten

Aktienkurs
33.33
Täglich Wechseln
-0.03 -0.09%
Monatlich
19.04%
Jährlich
21.02%
Q2 Prognose
32.39




Umsatzkosten Veränderung Datum
AbbVie USD 4.55B 757M 2025-12
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
ALKERMES USD 46.21M 5.38M 2025-12
Amgen USD 1.79B 128M 2025-12
Biogen USD 810.1M 205.1M 2025-09
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
J&J USD 7.97B 689M 2025-12
Merck USD 3.32B 531M 2025-12
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Otsuka Holdings JPY 192.74B 11.78B 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12